FHL1 as a prognostic biomarker and therapeutic target in acute promyelocytic leukaemia
Abstract Acute myeloid leukemia (AML) has a poor prognosis and high heterogeneity. Most cases of leukemias are caused by environmental factors interacting with the cell’s genetic material, but treatment is still dominated by cell cycle drugs. Therefore, there is an urgent need to find reliable bioma...
Saved in:
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Springer
2025-01-01
|
| Series: | Discover Oncology |
| Online Access: | https://doi.org/10.1007/s12672-025-01738-6 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832594624460357632 |
|---|---|
| author | Bo Luo Wei Li Jingyuan Zeng Yingyu Mao Shuang He Nan Hu Qulian Guo Xiaoli Zheng |
| author_facet | Bo Luo Wei Li Jingyuan Zeng Yingyu Mao Shuang He Nan Hu Qulian Guo Xiaoli Zheng |
| author_sort | Bo Luo |
| collection | DOAJ |
| description | Abstract Acute myeloid leukemia (AML) has a poor prognosis and high heterogeneity. Most cases of leukemias are caused by environmental factors interacting with the cell’s genetic material, but treatment is still dominated by cell cycle drugs. Therefore, there is an urgent need to find reliable biomarkers. Based on the Gene Expression Omnibus database, Kaplan–Meier survival analysis and univariate Cox regression analysis were used to select the genes that had the most significant influence on the prognosis of patients with AML. Quantitative real-time PCR and Western blot were used to assess the effects of small interfering RNA transfection and lentiviral interference on the gene's knockout and overexpression, respectively. These method were also used to confirm the expression levels of the FHL1 gene in the HL60 cell line compared to neutrophils.. Cell Counting Kit-8 and flow cytometry were used to detect the effect of high or low expression of FHL1 on cell viability and apoptosis under the influence of cytarabine and daunorubicin. FHL1 was found to be the most prognostic independent biomarker by GSE12417 screening and GSE37642 validation. FHL1 is highly expressed in AML, and knockdown of FHL1 can increase the sensitivity of AML cells to cytarabine and daunorubicin. FHL1 may play a role as a potential molecular marker and therapeutic target for predicting poor prognosis of AML and for direct treatment (chemotherapy). |
| format | Article |
| id | doaj-art-69bc37844b4643e6930f5afb525b8df0 |
| institution | Kabale University |
| issn | 2730-6011 |
| language | English |
| publishDate | 2025-01-01 |
| publisher | Springer |
| record_format | Article |
| series | Discover Oncology |
| spelling | doaj-art-69bc37844b4643e6930f5afb525b8df02025-01-19T12:29:20ZengSpringerDiscover Oncology2730-60112025-01-0116111110.1007/s12672-025-01738-6FHL1 as a prognostic biomarker and therapeutic target in acute promyelocytic leukaemiaBo Luo0Wei Li1Jingyuan Zeng2Yingyu Mao3Shuang He4Nan Hu5Qulian Guo6Xiaoli Zheng7Basic Medical School, Southwest Medical UniversityEnyang District People’s Hospital of Bazhong CitySchool of Nursing, Southwest Medical UniversityBasic Medical School, Southwest Medical UniversitySchool of Public Health, Southwest Medical UniversityBasic Medical School, Southwest Medical UniversityDepartment of Pediatrics, Children Hematological Oncology and Birth Defects Laboratory, Sichuan Clinical Research Center for Birth Defects, The Affiliated Hospital of Southwest Medical UniversityBasic Medical School, Southwest Medical UniversityAbstract Acute myeloid leukemia (AML) has a poor prognosis and high heterogeneity. Most cases of leukemias are caused by environmental factors interacting with the cell’s genetic material, but treatment is still dominated by cell cycle drugs. Therefore, there is an urgent need to find reliable biomarkers. Based on the Gene Expression Omnibus database, Kaplan–Meier survival analysis and univariate Cox regression analysis were used to select the genes that had the most significant influence on the prognosis of patients with AML. Quantitative real-time PCR and Western blot were used to assess the effects of small interfering RNA transfection and lentiviral interference on the gene's knockout and overexpression, respectively. These method were also used to confirm the expression levels of the FHL1 gene in the HL60 cell line compared to neutrophils.. Cell Counting Kit-8 and flow cytometry were used to detect the effect of high or low expression of FHL1 on cell viability and apoptosis under the influence of cytarabine and daunorubicin. FHL1 was found to be the most prognostic independent biomarker by GSE12417 screening and GSE37642 validation. FHL1 is highly expressed in AML, and knockdown of FHL1 can increase the sensitivity of AML cells to cytarabine and daunorubicin. FHL1 may play a role as a potential molecular marker and therapeutic target for predicting poor prognosis of AML and for direct treatment (chemotherapy).https://doi.org/10.1007/s12672-025-01738-6 |
| spellingShingle | Bo Luo Wei Li Jingyuan Zeng Yingyu Mao Shuang He Nan Hu Qulian Guo Xiaoli Zheng FHL1 as a prognostic biomarker and therapeutic target in acute promyelocytic leukaemia Discover Oncology |
| title | FHL1 as a prognostic biomarker and therapeutic target in acute promyelocytic leukaemia |
| title_full | FHL1 as a prognostic biomarker and therapeutic target in acute promyelocytic leukaemia |
| title_fullStr | FHL1 as a prognostic biomarker and therapeutic target in acute promyelocytic leukaemia |
| title_full_unstemmed | FHL1 as a prognostic biomarker and therapeutic target in acute promyelocytic leukaemia |
| title_short | FHL1 as a prognostic biomarker and therapeutic target in acute promyelocytic leukaemia |
| title_sort | fhl1 as a prognostic biomarker and therapeutic target in acute promyelocytic leukaemia |
| url | https://doi.org/10.1007/s12672-025-01738-6 |
| work_keys_str_mv | AT boluo fhl1asaprognosticbiomarkerandtherapeutictargetinacutepromyelocyticleukaemia AT weili fhl1asaprognosticbiomarkerandtherapeutictargetinacutepromyelocyticleukaemia AT jingyuanzeng fhl1asaprognosticbiomarkerandtherapeutictargetinacutepromyelocyticleukaemia AT yingyumao fhl1asaprognosticbiomarkerandtherapeutictargetinacutepromyelocyticleukaemia AT shuanghe fhl1asaprognosticbiomarkerandtherapeutictargetinacutepromyelocyticleukaemia AT nanhu fhl1asaprognosticbiomarkerandtherapeutictargetinacutepromyelocyticleukaemia AT qulianguo fhl1asaprognosticbiomarkerandtherapeutictargetinacutepromyelocyticleukaemia AT xiaolizheng fhl1asaprognosticbiomarkerandtherapeutictargetinacutepromyelocyticleukaemia |